Ethamsylate (diethylammonium 2,5-dihydroxybenzenesulphonate) is a non-steroidal drug that reduces bleeding from small vessels. The results of a double blind multicentre study showed that there were fewer severe periventricular haemorrhages among the survivors of a group of very low birthweight infants treated with this drug shortly after birth.1 The mode of action remains to be clearly elucidated but experimental evidence shows an inhibition of the products of the prostaglandin pathway.2 A group of very low birthweight infants with respiratory distress syndrome treated with ethamsylate had lower serum concentrations of immunoreactive prostacyclin metabolite than an untreated control group,3 and one interpretation was that the drug limited prostacyclin release from ischaemic brain, perhaps preventing bleeding secondary to the presence of this potent vasodilating and platelet disaggregating substance.
Prostaglandins are known to play a part in cerebral blood flow. Indomethacin inhibits prostaglandin production although at a different enzymatic point than that thought to be affected by ethamsylate. Studies in animals, adult humans, and babies attest to the reduction in cerebral blood flow velocity after treatment with indomethacin. The tendency to lower cerebral blood flow velocity in this group was not explained and was not followed by more intraventricular haemorrhages (one in each group).
Discussion
In this group of premature babies ethamsylate had no effect on cerebral blood flow velocity, Pourcelot index, or cardiac output.
Reduction of cerebral blood flow after treatment with indomethacin occurs after a few minutes, and one interpretation is that these effects cannot therefore be due to prostaglandin inhibition, which takes at least 30 minutes and perhaps as long as two hours to occur.6 An effect mediated by some factor associated with the structure of indomethacin would also explain the observations that a reduction in cerebral blood flow velocity has not been seen with other prostaglandin synthetase inhibitors such as aspirin, and that one hour after the administration of identical doses of indomethacin given at different rates only those infants who received a rapidly administered dose had reduced cerebral blood flow velocity. Aspirin is a more potent inhibitor of prostaglandin synthesis than ethamsylate, and prolongs the bleeding time in the same way as indomethacin, an effect not seen in preterm babies treated with ethamsylate. 3 The concern about possible ischaemic damage caused by a reduction in cerebral blood flow after rapid administration of indomethacin does not seem to apply to ethamsylate. It may be that a reduction in the incidence of neurodevelopmental handicap will be associated with fewer grade 2 and 3 periventricular haemorrhages in the survivors treated with ethamsylate, but meanwhile it would seem a safe choice for those who wish to use pharmacological prophylaxis in the nursery.
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